4. Conclusions
While wehave a generalunderstanding oftheprocess toprepare heparins and LMWHs, the specifics of individual manufacturing processes are trade secrets (Bhaskar et al., 2012; Linhardt & Gunay, 1999). Moreover, such process steps can also take place to the crude heparin, at either the slaughterhouse or consolidator levels, before it moves to a cGMP facility under regulatory oversight. This makes their detection only possible through forensic analysis. The analyses described in this manuscript provide some insights into the differences in such processes. The strength ofthe oxidation step can lead to the oxidation and the use of peracetic acid in the bleaching step can lead to acetylation of the serine residue in the pG chains of a heparin product. Thus, the modification of the serine residue can serve as an indication of these process steps. These pG chains are only present in very minor amounts within a heparin product, which is primarily composed of GAG chains. Thus, modern analytical methods together with the preparation of oligosaccharide standards offer an approach to better understand and ultimately control these process artifacts.